.Pharmacolibrary.Drugs.ATC.D.D06BB10 .Pharmacolibrary.Drugs.ATC.D.D06BB10| name: | Imiquimod |
| ATC code: | D06BB10 | route: | topical |
| n-compartments | 1 |
Imiquimod is an immune response modifier used topically for the treatment of various dermatological conditions such as actinic keratosis, superficial basal cell carcinoma, and external genital warts. It is approved and widely used in clinical practice for these indications.
Pharmacokinetic parameters estimated for healthy adult humans following topical administration, as clinical absorption is minimal and most studies report limited systemic exposure.
Garcia-Mouronte, E, et al., & Bea-Ardebol, S (2023). Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer. International journal of molecular sciences 24(13) –. DOI:10.3390/ijms241310835 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37446011
Dai, X, et al., & Donnelly, RF (2024). Calcipotriol Nanosuspension-Loaded Trilayer Dissolving Microneedle Patches for the Treatment of Psoriasis: In Vitro Delivery and In Vivo Antipsoriatic Activity Studies. Molecular pharmaceutics 21(6) 2813–2827. DOI:10.1021/acs.molpharmaceut.3c01223 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38752564
Lotlikar, VB, et al., & Londhe, VY (2025). Unlocking relief: formulation, characterization, and in vivo assessment of salicylic acid-loaded microemulgel for psoriasis management. Naunyn-Schmiedeberg's archives of pharmacology 398(3) 3037–3047. DOI:10.1007/s00210-024-03447-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39325151